ELEVANCE HEALTH ($ELV) posted quarterly earnings results for Q1 2026 on Wednesday, April 22nd. The company reported earnings of $12.58 per share, beating estimates of $10.89 by $1.69. The company also reported revenue of $49,494,000,000, beating estimates of $48,785,110,253 by $708,889,747.
You can see Quiver Quantitative's $ELV stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ELEVANCE HEALTH Insider Trading Activity
ELEVANCE HEALTH insiders have traded $ELV stock on the open market 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $ELV stock by insiders over the last 6 months:
- CHARLES MORGAN JR KENDRICK (EVP & President, Commercial) sold 3,196 shares for an estimated $910,604
- STEVEN H COLLIS purchased 3,000 shares for an estimated $869,519
- AMY W SCHULMAN sold 26 shares for an estimated $7,475
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ELEVANCE HEALTH Hedge Fund Activity
We have seen 628 institutional investors add shares of ELEVANCE HEALTH stock to their portfolio, and 784 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 7,196,465 shares (-75.4%) from their portfolio in Q4 2025, for an estimated $2,522,720,805
- WELLINGTON MANAGEMENT GROUP LLP added 1,668,679 shares (+25.2%) to their portfolio in Q4 2025, for an estimated $584,955,423
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,607,274 shares (+27.5%) to their portfolio in Q4 2025, for an estimated $563,429,900
- HARRIS ASSOCIATES L P added 1,604,821 shares (+50.3%) to their portfolio in Q4 2025, for an estimated $562,570,001
- CAPITAL INTERNATIONAL INVESTORS removed 1,367,274 shares (-46.3%) from their portfolio in Q4 2025, for an estimated $479,297,900
- INVESCO LTD. added 1,306,390 shares (+50.3%) to their portfolio in Q4 2025, for an estimated $457,955,014
- CITADEL ADVISORS LLC added 1,244,783 shares (+294.1%) to their portfolio in Q4 2025, for an estimated $436,358,680
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ELEVANCE HEALTH Government Contracts
We have seen $260,356,143 of award payments to $ELV over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- PART A/PART B MEDICARE ADMINISTRATIVE CONTRACTOR (MAC) JURISDICTION K (JK): $86,075,650
- J6 A/B MAC SERVICES: $79,174,247
- NEXT GENERATION DESKTOP IGF::OT::IGF: $74,589,844
- SPARC WILL BE THE MAJOR CONTRACT VEHICLE FOR CMS IT SYSTEMS AND SUPPORT HHS OPDIVS CAN ALSO MAKE USE OF SPA...: $11,890,083
- THE CONTRACTOR SHALL PROVIDE SUPPLIES AND/OR SERVICES TO PROVIDE A SINGLE FRONT-END SOLUTION FOR THE SUBMIS...: $4,213,107
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
ELEVANCE HEALTH Congressional Stock Trading
Members of Congress have traded $ELV stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ELV stock by members of Congress over the last 6 months:
- SENATOR MARKWAYNE MULLIN purchased up to $50,000 on 12/29.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
ELEVANCE HEALTH Analyst Ratings
Wall Street analysts have issued reports on $ELV in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 01/30/2026
- Wells Fargo issued a "Overweight" rating on 01/30/2026
- TD Cowen issued a "Buy" rating on 11/26/2025
- Mizuho issued a "Outperform" rating on 11/04/2025
- JP Morgan issued a "Overweight" rating on 10/28/2025
To track analyst ratings and price targets for ELEVANCE HEALTH, check out Quiver Quantitative's $ELV forecast page.
ELEVANCE HEALTH Price Targets
Multiple analysts have issued price targets for $ELV recently. We have seen 12 analysts offer price targets for $ELV in the last 6 months, with a median target of $391.0.
Here are some recent targets:
- David Windley from Jefferies set a target price of $391.0 on 04/20/2026
- David Macdonald from Truist Securities set a target price of $375.0 on 04/13/2026
- Elizabeth Anderson from Evercore ISI Group set a target price of $345.0 on 04/08/2026
- Ann Hynes from Mizuho set a target price of $350.0 on 03/11/2026
- Lisa Gill from JP Morgan set a target price of $397.0 on 02/02/2026
- Andrew Mok from Barclays set a target price of $393.0 on 01/30/2026
- Stephen Baxter from Wells Fargo set a target price of $391.0 on 01/30/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
